Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.
Seeing a return on investment in pharma marketing means understanding what happens to every dollar.
Those challengers who address critical patient needs beyond traditional treatment will become a force to be reckoned with.
Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.
From Walmart to Amazon to 23andMe, these 11 market scenarios paint a picture of what disruption looks like, both in and out of healthcare.
Purposeful collaboration will help more people understand how their daily decisions dictate their health.
How pharmaceutical companies can better define, measure, and deliver value to patients.
Traditional retailers are now getting into the health business. What does it all mean, and where should corporate directors focus next?
Our new advice for the Blues, who are in a formative period as market trends create both sizable risk and sizable opportunity.
An examination of how the astronomically deadly and expensive opioid epidemic has generated significant litigation risk for healthcare businesses.